UniProt P30656
Proteasome subunit beta type-5 (P30656)
Proteasome subunit beta type-5 (UniProt P30656), EC 3.4.25.1: 542 experimental structures on GenesisL1, 37 ligands bound, 86 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- P30656
- Protein
- Proteasome subunit beta type-5
- EC
- 3.4.25.1
- Experimental structures
- 542
- Predicted models
- 0
- Ligands
- 37
- Pockets
- 86 · 23 records with a druggable one
Structures
542 records of P30656 in the MolNFT archive: 542 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1FNT | Crystal structure of the 20S proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | L, Z | — | — |
| 1FNT | Crystal structure of the 20S proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | L, Z | — | — |
| 1G0U | A gated channel into the proteasome core particle | x-ray diffraction | K, Y | — | — |
| 1G0U | A gated channel into the proteasome core particle | x-ray diffraction | K, Y | — | — |
| 1G65 | Crystal structure of epoxomicin:20s proteasome reveals a molecular basis for selectivity of… | x-ray diffraction | K, Y | — | — |
| 1G65 | Crystal structure of EPOXOMICIN:20S proteasome reveals a molecular basis for selectivity of… | x-ray diffraction | K, Y | — | — |
| 1JD2 | Crystal Structure of the yeast 20S Proteasome:TMC-95A complex: A non-covalent Proteasome Inhibitor | x-ray diffraction | K, R | — | — |
| 1JD2 | Crystal structure of the yeast 20S PROTEASOME:TMC-95A complex: a non- covalent proteasome inhibitor | x-ray diffraction | K, R | — | — |
| 1RYP | Crystal structure of the 20S proteasome from yeast at 2.4 ångströms resolution | x-ray diffraction | L, Z | — | — |
| 1RYP | Crystal structure of the 20S proteasome from yeast at 2.4 ångströms resolution | x-ray diffraction | L, Z | — | — |
| 1Z7Q | Crystal structure of the 20s proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | L, Z | — | — |
| 1Z7Q | Crystal structure of the 20S proteasome from yeast in complex with the proteasome activator PA26… | x-ray diffraction | L, Z | — | — |
| 2F16 | Crystal structure of the yeast 20S proteasome in complex with bortezomib | x-ray diffraction | K, Y | — | — |
| 2F16 | Crystal structure of the yeast 20S proteasome in complex with bortezomib | x-ray diffraction | K, Y | — | — |
| 2FAK | Crystal structure of Salinosporamide A in complex with the yeast 20S proteasome | x-ray diffraction | K, Y | — | — |
| 2FAK | Crystal structure of salinosporamide a in complex with the yeast 20S proteasome | x-ray diffraction | K, Y | — | — |
| 2GPL | TMC-95 based biphenyl-ether macrocycles: specific proteasome inhibitors | x-ray diffraction | K, Y | — | — |
| 2GPL | Tmc-95 based biphenyl-ether macrocycles: specific proteasome inhibitors | x-ray diffraction | K, Y | — | — |
| 2ZCY | yeast 20S proteasome:syringolin A-complex | x-ray diffraction | K, Y | — | — |
| 2ZCY | Yeast 20S PROTEASOME:SYRINGOLIN a-complex | x-ray diffraction | K, Y | — | — |
| 3BDM | yeast 20S proteasome:glidobactin A-complex | x-ray diffraction | K, Y | — | — |
| 3BDM | Yeast 20S PROTEASOME:GLIDOBACTIN a-complex | x-ray diffraction | K, Y | — | — |
| 3D29 | Proteasome inhibition by fellutamide B | x-ray diffraction | K, Y | — | — |
| 3DY3 | Crystal structure of yeast 20S proteasome in complex with the epimer form of spirolactacystin | x-ray diffraction | K, Y | — | — |
| 3DY3 | Crystal structure of yeast 20S proteasome in complex with the epimer form of spirolactacystin | x-ray diffraction | K, Y | — | — |
| 3DY4 | Crystal structure of yeast 20S proteasome in complex with spirolactacystin | x-ray diffraction | K, Y | — | — |
| 3DY4 | Crystal structure of yeast 20S proteasome in complex with spirolactacystin | x-ray diffraction | K, Y | — | — |
| 3E47 | Crystal Structure of the Yeast 20S Proteasome in Complex with Homobelactosin C | x-ray diffraction | K, Y | — | — |
| 3E47 | Crystal structure of the yeast 20S proteasome in complex with homobelactosin C | x-ray diffraction | K, Y | — | — |
| 3GPJ | Crystal structure of the yeast 20S proteasome in complex with syringolin B | x-ray diffraction | K, Y | — | — |
| 3GPJ | Crystal structure of the yeast 20S proteasome in complex with syringolin B | x-ray diffraction | K, Y | — | — |
| 3GPT | Crystal structure of the yeast 20S proteasome in complex with Salinosporamide derivatives: slow… | x-ray diffraction | K, Y | — | — |
| 3GPT | Crystal structure of the yeast 20S proteasome in complex with salinosporamide derivatives: slow… | x-ray diffraction | K, Y | — | — |
| 3GPW | Crystal structure of the yeast 20S proteasome in complex with Salinosporamide derivatives… | x-ray diffraction | K, Y | — | — |
| 3GPW | Crystal structure of the yeast 20S proteasome in complex with salinosporamide derivatives… | x-ray diffraction | K, Y | — | — |
| 3HYE | Crystal structure of 20S proteasome in complex with hydroxylated salinosporamide | x-ray diffraction | K, Y | — | — |
| 3HYE | Crystal structure of 20S proteasome in complex with hydroxylated salinosporamide | x-ray diffraction | K, Y | — | — |
| 3JCO | Structure of yeast 26S proteasome in M1 state derived from Titan dataset | electron microscopy | 7, l | — | — |
| 3JCP | Structure of yeast 26S proteasome in M2 state derived from Titan dataset | electron microscopy | 7, l | — | — |
| 3MG0 | Structure of yeast 20S proteasome with bortezomib | x-ray diffraction | K, Y | — | — |
| 3MG0 | Structure of yeast 20S proteasome with bortezomib | x-ray diffraction | K, Y | — | — |
| 3MG4 | Structure of yeast 20S proteasome with Compound 1 | x-ray diffraction | K, Y | — | — |
| 3MG4 | Structure of yeast 20S proteasome with compound 1 | x-ray diffraction | K, Y | — | — |
| 3MG6 | Structure of yeast 20S open-gate proteasome with Compound 6 | x-ray diffraction | K, Y | — | — |
| 3MG6 | Structure of yeast 20S open-gate proteasome with compound 6 | x-ray diffraction | K, Y | — | — |
| 3MG7 | Structure of yeast 20S open-gate proteasome with Compound 8 | x-ray diffraction | K, Y | — | — |
| 3MG7 | Structure of yeast 20S open-gate proteasome with compound 8 | x-ray diffraction | K, Y | — | — |
| 3MG8 | Structure of yeast 20S open-gate proteasome with Compound 16 | x-ray diffraction | K, Y | — | — |
| 3MG8 | Structure of yeast 20S open-gate proteasome with compound 16 | x-ray diffraction | K, Y | — | — |
| 3NZJ | Crystal structure of yeast 20S proteasome in complex with ligand 2a | x-ray diffraction | K, Y | — | — |
| 3NZJ | Crystal structure of yeast 20S proteasome in complex with ligand 2A | x-ray diffraction | K, Y | — | — |
| 3NZW | Crystal structure of the yeast 20S proteasome in complex with 2b | x-ray diffraction | K, Y | — | — |
| 3NZW | Crystal structure of the yeast 20S proteasome in complex with 2B | x-ray diffraction | K, Y | — | — |
| 3NZX | Crystal structure of the yeast 20S proteasome in complex with ligand 2c | x-ray diffraction | K, Y | — | — |
| 3NZX | Crystal structure of the yeast 20S proteasome in complex with ligand 2C | x-ray diffraction | K, Y | — | — |
| 3OEU | Structure of yeast 20S open-gate proteasome with Compound 24 | x-ray diffraction | K, Y | — | — |
| 3OEU | Structure of yeast 20S open-gate proteasome with compound 24 | x-ray diffraction | K, Y | — | — |
| 3OEV | Structure of yeast 20S open-gate proteasome with Compound 25 | x-ray diffraction | K, Y | — | — |
| 3OEV | Structure of yeast 20S open-gate proteasome with compound 25 | x-ray diffraction | K, Y | — | — |
| 3OKJ | Alpha-keto-aldehyde binding mechanism reveals a novel lead structure motif for proteasome inhibition | x-ray diffraction | K, Y | — | — |
482 records more on the page itself.
Ligands
- MG · Magnesium ion · in 156 records
- 79P · (2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 8 records
- BO2 · N-[(1R)-1-(dihydroxyboryl)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide · in 8 records
- 04C · 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol · in 7 records
- 3BV · N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide · in 7 records
- 6N5 · ~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide · in 7 records
- 39V · N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S, 4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide · in 6 records
- 6NV · ~{N}-[(2~{R})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide · in 6 records
- GQQ · ~{N}-[(2~{S})-1-[[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]pyrazine-2-carboxamide · in 6 records
- GRT · (2~{S})-~{N}-[2-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-2-oxidanylidene-ethyl]-2-[[(2~{S})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 6 records
- GTW · ~{N}-[(2~{S})-1-[[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-cyclohexyl-1-oxidanylidene-propan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide · in 6 records
- GQH · (2~{S})-~{N}-[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl) phenyl]-4-methylsulfonyl-butan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-2-[[(2~{S})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 5 records
- GQK · (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{R})-4-methyl-3,4-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 5 records
- GRW · (2~{S})-~{N}-[(2~{S},3~{R})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-oxidanyl-1-oxidanylidene-butan-2-yl]-2-[[(2~{R})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 5 records
- GT5 · ~{N}-[(2~{S})-1-[[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl)phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-methoxy-1-oxidanylidene-propan-2-yl]amino]-4-methyl-1-oxidanylidene-pentan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide · in 5 records
- GT8 · (2~{S})-~{N}-[(3~{S},4~{R})-1-cyclohexyl-5-methyl-4,5-bis(oxidanyl)hexan-3-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 5 records
- 79L · (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 4 records
- GQT · (2~{S})-~{N}-[(2~{S})-1-[[(2~{S})-1-[4-(aminomethyl) phenyl]-4-methylsulfonyl-butan-2-yl]amino]-3-oxidanyl-1-oxidanylidene-propan-2-yl]-2-[[(2~{S})-2-azido-3-phenyl-propanoyl]amino]-4-methyl-pentanamide · in 4 records
- EQE · (2~{S},3~{R})-4-[[(2~{S})-3-methyl-1-[[(2~{S})-3-methyl-1-oxidanylidene-1-phenylmethoxy-butan-2-yl]amino]-1-oxidanylidene-butan-2-yl]amino]-3-oxidanyl-4-oxidanylidene-2-propan-2-yl-butanoic acid · in 2 records
- F6K · Homosalinosporamide A - bound form · in 2 records
- FGY · N-(2,2-dimethylpropyl)-N~2~-[4-(hydroxycarbamoyl) benzene-1-carbonyl]-L-asparaginyl-N-benzyl-L-alaninamide · in 2 records
- GVW · (2~{S})-~{N}-[(2~{S},3~{R})-1-[(4~{A}~{S},8~{A}~{S})-1, 2,3,4,4~{A},5,6,7,8,8~{A}-decahydronaphthalen-2-yl]-4-methyl-3,4-bis(oxidanyl)pentan-2-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide · in 2 records
- GWK · (2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{R})-4-methyl-1-(4-methylcyclohexyl)-3,4-bis(oxidanyl)pentan-2-yl]-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino) propanoyl]amino]propanamide · in 2 records
- GWT · (2~{S})-~{N}-[(2~{S},3~{R})-1-(4-cyclohexylcyclohexyl)-4-methyl-3,4-bis(oxidanyl)pentan-2-yl]-3-(4-methoxyphenyl)-2-[[(2~{S})-2-(2-morpholin-4-ium-4-ylethanoylamino)propanoyl]amino]propanamide · in 2 records
- GWZ · (2~{S})-~{N}-[(2~{S})-1-[[(3~{R},4~{S})-2,6-dimethyl-2, 3-bis(oxidanyl)heptan-4-yl]amino]-1-oxidanylidene-3-phenyl-propan-2-yl]-4-methyl-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino)-4-phenyl-butanoyl]amino]pentanamide · in 2 records
- QOE · (2~{S},3~{R})-~{N}-[(5~{S},8~{S},10~{S})-5-methyl-10-oxidanyl-2,7-bis(oxidanylidene)-1,6-diazacyclododec-8-yl]-3-oxidanyl-2-(3-phenylpropanoylamino)butanamide · in 2 records
- 38X · N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S, 4R)-1-cyclohexyl-5-hydroxy-4-methyl-3-oxopentan-2-yl]-L-tryptophanamide · in 1 record
- 3K4 · (2S,3S)-3-methylaziridine-2-carboxylic acid · in 1 record
- 5BY · {2-[2-(2-{4-[(1E)-4-{[(2S)-1-{[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]amino}-1-oxo-3-phenylpropan-2-yl]amino}-4-oxobut-1-en-1-yl]-1H-1,2,3-triazol-1-yl}ethoxy)ethoxy]ethoxy}acetic acid · in 1 record
- 5BZ · [(1~{R})-1-[[(2~{S})-2-(hex-5-ynoylamino)-3-phenyl-propanoyl]amino]-3-methyl-butyl]boronic acid · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.